Skip to main content

Table 1 Intogen significantly enriched pathways

From: Complete response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS/AKT mutations and high tumour mutational burden

ID Pathway Z score p value Q value
hsa05210 Colorectal cancer 8.14 1.88E−16 1.62E−14
hsa05222 Small cell lung cancer 6.73 8.43E−12 3.63E−10
hsa04150 mTOR signalling pathway 6.10 4.99E−10 1.43E−08
hsa04310 Wnt signalling pathway 5.96 1.26E−09 2.71E−08
hsa05212 Pancreatic cancer 5.77 3.91E−09 6.60E−08
hsa00562 Inositol phosphate metabolism 5.71 5.37E−09 6.60E−08
hsa04070 Phosphatidylinositol signalling system 5.71 5.37E−09 6.60E−08
hsa04115 p53 signalling pathway 5.60 1.01E−08 1.09E−07
hsa05166 Human T-cell leukemia virus 1 infection 5.50 1.87E−08 1.79E−07
hsa05169 Epstein-Barr virus infection 4.99 2.96E−07 2.12E−06
hsa05162 Measles 4.99 2.96E−07 2.12E−06
hsa04210 Apoptosis 4.99 2.96E−07 2.12E−06
hsa05217 Basal cell carcinoma 4.66 1.56E−06 1.03E−05
hsa04120 Ubiquitin mediated proteolysis 4.59 2.16E−06 1.33E−05